Studies show that treatment is less costly and has lower
hospital re-admissions
MARLBOROUGH, Massachusetts,
June 14, 2016 /PRNewswire/
-- Boston Scientific Corporation (NYSE: BSX) today announced
that its GreenLight XPS™ Laser Therapy System, used for the
treatment of prostatic enlargement, known as benign prostatic
hyperplasia (BPH), received positive guidance from the National
Institute for Health and Care Excellence (NICE). NICE provides
evidenced-based guidance, advice and standards for the National
Health Service (NHS) in England in
order to improve outcomes for patients.
In its evaluation, NICE concluded that the adoption of the
GreenLight XPS Laser Therapy System to treat non high-risk patients
with BPH can significantly reduce costs for the NHS. NICE estimates
that broad adoption of the GreenLight XPS Laser System over the
current traditional surgical treatment, transurethral resection of
the prostate (TURP), could result in savings of around £2.3 million
and possibly up to £3.2 million annually for the NHS as the
GreenLight XPS System therapy is typically done on an outpatient
day-case basis. The British Association for Day Case Surgery (BADS
2013) has recommended that within the next five years, more than 90
percent of urological surgery should be done as day-case
procedures.
"The GreenLight XPS System is a well-established treatment to
help men with BPH," said Mr. Gordon
Muir, consultant urological surgeon, King's College
Hospital, London, England. "It is
suitable for almost all men, even those who may not be deemed fit
for conventional surgery. The positive guidance from NICE will give
more men access to the GreenLight XPS System and may allow
surgeons to treat patients on an outpatient basis, with excellent
outcomes and with fewer complications."
The NICE evaluation team examined information submitted by the
company along with independently sourced clinical studies including
the GOLIATH study, a randomized prospective trial of 291 patients
conducted in nine European countries that compared the GreenLight
XPS System to TURP. This study demonstrated that the laser therapy
has fewer initial serious post-procedure complications, with lower
hospital re-admissions and outcomes that are equally effective as
the current standard surgical treatment 1,2.
"Using technology to improve care and lower health care costs
directly benefits patients, hospitals and providers," said
Michael Phalen, executive vice
president and president, MedSurg, Boston Scientific. "NICE is
internationally recognized for its evidence-based review process
and this guidance demonstrates the importance of continually
evaluating how we can make improvements in caring for
patients."
More than 110 million men worldwide are diagnosed with BPH, an
enlargement of the prostate that occurs naturally with age and is
one of the most common diseases among aging men3. It
affects 50 percent of men between the ages of 51 and 60 and 90
percent of men over the age of 804. BPH causes a number
of symptoms and, if untreated, can result in infections, renal
failure and kidney stones4,5. A variety of treatment
options are used to treat BPH including medication, surgery and
laser therapy.
For more product and important safety information, please visit
the GreenLight XPS System site. Or follow Boston Scientific Urology
on Twitter at @bsc_urology.
Boston Scientific
Boston Scientific transforms lives through innovative medical
solutions that improve the health of patients around the world. As
a global medical technology leader for more than 35 years, we
advance science for life by providing a broad range of high
performance solutions that address unmet patient needs and reduce
the cost of healthcare. For more information, visit
www.bostonscientific.com and connect on Twitter and Facebook.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. Forward-looking
statements may be identified by words like "anticipate," "expect,"
"project," "believe," "plan," "estimate," "intend" and similar
words. These forward-looking statements are based on our beliefs,
assumptions and estimates using information available to us at the
time and are not intended to be guarantees of future events or
performance. These forward-looking statements include, among other
things, statements regarding the guidance from NICE and product
performance and impact. If our underlying assumptions turn out to
be incorrect, or if certain risks or uncertainties materialize,
actual results could vary materially from the expectations and
projections expressed or implied by our forward-looking statements.
These factors, in some cases, have affected and in the future
(together with other factors) could affect our ability to implement
our business strategy and may cause actual results to differ
materially from those contemplated by the statements expressed in
this press release. As a result, readers are cautioned not to place
undue reliance on any of our forward-looking statements.
Factors that may cause such differences include, among other
things: future economic, competitive, reimbursement and regulatory
conditions; new product introductions; demographic trends;
intellectual property; litigation; financial market conditions; and
future business decisions made by us and our competitors. All of
these factors are difficult or impossible to predict accurately and
many of them are beyond our control. For a further list and
description of these and other important risks and uncertainties
that may affect our future operations, see Part I, Item 1A – Risk
Factors in our most recent Annual Report on Form 10-K filed with
the Securities and Exchange Commission, which we may update in Part
II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we
have filed or will file hereafter. We disclaim any intention or
obligation to publicly update or revise any forward-looking
statements to reflect any change in our expectations or in events,
conditions or circumstances on which those expectations may be
based, or that may affect the likelihood that actual results will
differ from those contained in the forward-looking statements. This
cautionary statement is applicable to all forward-looking
statements contained in this document.
1. Data from initial 6 month endpoint of
GOLIATH study, XPS results in a lower rate of early reinterventions
but has a similar rate after 6 months. Bachmann A, et al. "180-W
XPS GreenLight laser vaporisation versus transurethral resection of
the prostate for the treatment of benign prostatic obstruction:
6-month safety and efficacy results of a European Multicentre
Randomised Trial--the GOLIATH study." European Urology 65.5 (2014):
931-42. Web.
2. Jovanovic, M., Zoran Dzamic,
Miodrag Acimovic, Boris Kajmakovic,
and Tomislav Pejcic. "Usage of
GreenLight HPS 180-W Laser Vaporisation for Treatment of Benign
Prostatic Hyperplasia." ACTA CHIR IUG Acta Chirurgica
Iugoslavica Acta Chir Iugo ACTA CHIR IUGOSL 61.1 (2014): 57-61.
Web.
3. "Prostate Enlargement: Benign
Prostatic Hyperplasia." Prostate Enlargement: Benign Prostatic
Hyperplasia. National Institute of Diabetes and Digestive and
Kidney Diseases, 1 Sept. 2014. Web.
10 June 2016.
4. Barry, Md M., and Md C. Roehrborn.
"Management of Benign Prostatic Hyperplasia." Annual Review of
Medicine Annu. Rev. Med. 48.1 (1997): 177-89. Print.
5. Benign enlargement of prostate. ADAM
Health Illustrated Encyclopedia.
http://www.healthline.com/adamcontent/enlarged-prostate. Accessed
Oct. 21, 2010.
6. NICE guidance, 'GreenLight XPS for
treating benign prostatic hyperplasia', www.nice.org.uk/mtg29.
CONTACTS:
Catherine
Brady
508-683-4797(office)
Media
Relations
Boston Scientific
Corporation
catherine.brady@bsci.com
European Media:
Chiara Ennas
+44 (0) 1442 411618 (office)
Boston Scientific Corporation
chiara.ennas@bsci.com
Investors:
Susie Lisa, CFA
508-683-5565 (office)
Investor Relations
Boston Scientific Corporation
investor_relations@bsci.com